TY - JOUR
T1 - Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis
T2 - EHA-ISA working group guidelines
AU - Sanchorawala, Vaishali
AU - Boccadoro, Mario
AU - Gertz, Morie
AU - Hegenbart, Ute
AU - Kastritis, Efstathios
AU - Landau, Heather
AU - Mollee, Peter
AU - Wechalekar, Ashutosh
AU - Palladini, Giovanni
N1 - Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - AL amyloidosis is a systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. High dose intravenous melphalan and autologous stem cell transplantation was developed for the treatment of AL amyloidosis in the early 1990s and was prompted by its success in multiple myeloma. This application has evolved significantly over the past three decades. These guidelines provide a comprehensive assessment of eligibility criteria, stem cell collection and mobilisation strategies and regimens, risk-adapted melphalan dosing, role for induction and consolidation therapies, specific supportive care management, long-term outcome with respect to survival, haematologic response and relapse and organ responses following stem cell transplantation. These guidelines are developed by the experts in the field on behalf of the stem cell transplant working group of the International Society of Amyloidosis (ISA) and European Haematology Association (EHA).
AB - AL amyloidosis is a systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. High dose intravenous melphalan and autologous stem cell transplantation was developed for the treatment of AL amyloidosis in the early 1990s and was prompted by its success in multiple myeloma. This application has evolved significantly over the past three decades. These guidelines provide a comprehensive assessment of eligibility criteria, stem cell collection and mobilisation strategies and regimens, risk-adapted melphalan dosing, role for induction and consolidation therapies, specific supportive care management, long-term outcome with respect to survival, haematologic response and relapse and organ responses following stem cell transplantation. These guidelines are developed by the experts in the field on behalf of the stem cell transplant working group of the International Society of Amyloidosis (ISA) and European Haematology Association (EHA).
KW - AL amyloidosis
KW - melphalan
KW - patient selection
KW - stem cell transplantation
KW - supportive care
UR - http://www.scopus.com/inward/record.url?scp=85119346648&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119346648&partnerID=8YFLogxK
U2 - 10.1080/13506129.2021.2002841
DO - 10.1080/13506129.2021.2002841
M3 - Article
C2 - 34783272
AN - SCOPUS:85119346648
SN - 1350-6129
VL - 29
SP - 1
EP - 7
JO - Amyloid
JF - Amyloid
IS - 1
ER -